The cannabinoid receptor 1 (CB 1 ) is the principal target of the psychoactive constituent of marijuana, the partial agonist Δ 9 -tetrahydrocannabinol (Δ 9 -THC) 1 . Here we report two agonist-bound crystal structures of human CB 1 in complex with a tetrahydrocannabinol (AM11542) and a hexahydrocannabinol (AM841) at 2.80 Å and 2.95 Å resolution, respectively. The two CB 1 -agonist complexes reveal important conformational changes in the overall structure, relative to the antagonist-bound state 2 , including a 53% reduction in the volume of the ligand-binding pocket and an increase in the surface area of the G-proteinbinding region. In addition, a 'twin toggle switch' of Phe200 3.36 and Trp356 6.48 (superscripts denote Ballesteros-Weinstein numbering 3 ) is experimentally observed and appears to be essential for receptor activation. The structures reveal important insights into the activation mechanism of CB 1 and provide a molecular basis for predicting the binding modes of Δ 9 -THC, and endogenous and synthetic cannabinoids. The plasticity of the binding pocket of CB 1 seems to be a common feature among certain class A G-proteincoupled receptors. These findings should inspire the design of chemically diverse ligands with distinct pharmacological properties.
The cannabinoid receptor 1 (CB 1 ) is the principal target of the psychoactive constituent of marijuana, the partial agonist Δ 9 -tetrahydrocannabinol (Δ 9 -THC) 1 . Here we report two agonist-bound crystal structures of human CB 1 in complex with a tetrahydrocannabinol (AM11542) and a hexahydrocannabinol (AM841) at 2.80 Å and 2.95 Å resolution, respectively. The two CB 1 -agonist complexes reveal important conformational changes in the overall structure, relative to the antagonist-bound state 2 , including a 53% reduction in the volume of the ligand-binding pocket and an increase in the surface area of the G-proteinbinding region. In addition, a 'twin toggle switch' of Phe200 3.36 and Trp356 6 .48 (superscripts denote Ballesteros-Weinstein numbering 3 ) is experimentally observed and appears to be essential for receptor activation. The structures reveal important insights into the activation mechanism of CB 1 and provide a molecular basis for predicting the binding modes of Δ 9 -THC, and endogenous and synthetic cannabinoids. The plasticity of the binding pocket of CB 1 seems to be a common feature among certain class A G-proteincoupled receptors. These findings should inspire the design of chemically diverse ligands with distinct pharmacological properties.
Cannabis sativa L., commonly known as marijuana, has been used for medicinal and recreational purposes across different cultures for more than 5,000 years 4, 5 . The principal Cannabis constituent, Δ 9 -THC, exerts its psychotropic effects by activating CB 1 , which is also the primary target of the endocannabinoids, anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) 1, 6 . Structural examination of CB 1 in complex with the antagonist AM6538 2 and taranabant 7 provides molecular insights into the inactive state of the receptor, yet does not inform us as to how CB 1 elicits its diverse physiological effects.
To facilitate CB 1 crystallization in agonist-bound form, two potent CB 1 agonists, AM11542 and AM841, were designed to introduce a tricyclic terpenoid ring system, the 6aR, 10aR stereochemistry at the junction of the B-and C-rings and the phenolic hydroxyl group at C1, all of which also characterize the Δ 9 -THC tricyclic ring system (Fig. 1a , Methods and Extended Data Fig. 1 ). The two ligands used in this study differ from Δ 9 -THC by possessing a pivotal 1′ ,1′ -gem-dimethylheptyl (DMH) alkyl chain at the C3 position as well as bromo and isothiocyanato groups as ω -substituents for AM11542 and AM841, respectively (Fig. 1a) . Having high affinity for CB 1 and binding in a wash-resistant manner to the receptor (Fig. 1a-c) , both AM11542 and AM841 are potent, full agonists of CB 1 as determined by their ability to inhibit forskolin-stimulated accumulation of cAMP compared to CP55,940, whereas Δ 9 -THC acts as a partial agonist in this assay (Fig. 1d) . The two agonist-bound CB 1 structures were determined using a thermostabilizing construct as previously described 2 for CB 1 -AM6538
(Extended Data Fig. 2 , Extended Data Table 1 ). The receptor conformations of the AM11542-and AM841-bound complexes are very similar (C α root mean square deviation (r.m.s.d.) = 0.66 Å), and both ligands overlay well in the same binding pocket (Fig. 2a, Extended Data Fig. 3a) . Thus, we focus our discussions mainly on the higher resolution CB 1 -AM11542 structure, while mentioning specific differences of the AM841-bound complex where relevant. In contrast to a V-shaped loop in the CB 1 -AM6538 structure, the truncated N terminus resides over the ligand-binding pocket where it is not directly involved in agonist binding ( Fig. 2b) , although it does not preclude the possibility that there may be conformational changes in a full-length N-terminal domain. A cholesterol molecule, which is absent in the antagonist-bound structure, is observed between the cytoplasmic portion of helices II, III and IV in the agonist-bound complexes (Extended Data Fig. 3b ). This cholesterol binding cavity is revealed through a rotation of helix II coupled with conformational changes of the side chain of Leu165 2.52 (superscript denotes Ballesteros-Weinstein numbering 3 ). The agonist AM11542 adopts an L-shape conformation in the orthosteric-binding pocket, which is much smaller than the more expanded binding domain in the antagonist AM6538-bound structure ( Fig. 2b-d) . The interactions between AM11542 and CB 1 are mainly hydrophobic and aromatic, consisting of residues from extracellular loop 2 (ECL2), helices III, V, VI and VII (Fig. 3a, d) ( Fig. 3a, d ). In addition, the isothiocyanate moiety of AM841 forms a hydrogen bond with Tyr275 5.39 . Notably, Leu193 3.29 Ala and Tyr275 5.39 Ala mutations markedly decrease the potency of the agonists (Fig. 3c, Extended Data Fig. 4b , Extended Data Table 2 ). Structureactivity relationship (SAR) studies with classical cannabinoids have shown that the C3 alkyl chain lengths and ω -substitutions modulate ligand affinity. Also, incorporation of a C1′ -gem-dimethyl group affects the conformational properties of the alkyl chain and leads to notable enhancement in potency and efficacy [8] [9] [10] [11] . Unlike Δ 9 -THC, which has a shorter alkyl chain (n-pentyl), our results show that longer alkyl chains coupled with a C1′ -gem-dimethyl group allow extended interactions with CB 1 , while the C1′ -gem-dimethyl group forms hydrophobic interactions with Phe200 3.36 , Leu359
6.51 and Met363 6.55 (Fig. 3a, d ). Taken together, these data provide important insights into the key role of the DMH moiety in activating CB 1 .
On the basis of the AM11542-bound CB 1 structure and mutagenesis data 12 , we investigated the interactions of representative agonists from three different scaffolds (classical cannabinoids, endocannabinoids and aminoalkylindoles) with CB 1 through docking and molecular dynamics validation (Fig. 3e, f, Extended Data Fig. 5 ). The predicted binding mode of the classical cannabinoids Δ 9 -THC ( Fig. 3e ) and HU-210 (Extended Data Fig. 5g ) resembles that of AM11542 in the CB 1 crystal structure. HU-211, the enantiomer of HU-210, does not activate CB 1 13,14 as it exhibits severe clashes when superimposed with its active enantiomer HU-210 (Extended Data Fig. 5i ). The endocannabinoids AEA (Fig. 3f ) and 2-AG (Extended Data Fig. 5j ) adopt a C-shaped conformation and their long tails extend into the long channel. In comparison with other lipid receptors, such as sphingosine-1-phosphate receptor 1 (S1P 1 ), the alkyl chain of AM11542 and AM841 occupies a similar position as in 'arm 2' of the antagonist AM6538 2 , as well as the alkyl chain of ML056 in the S1P 1 receptor 15 ( Fig. 3b) , indicating that this could be a conserved binding pocket for alkyl chains within lipid-binding receptors. The structurally distinct aminoalkylindoles WIN 55,212-2 (Extended Data Fig. 5k ) and JWH-018 (Extended Data Fig. 5h ) occupy the same position in the pocket as AM11542 and AM841, exhibiting major π -π interactions with aromatic residues instead of hydrogen-bond interactions as observed in most classical cannabinoid-CB 1 interactions.
Comparisons between the agonist-and antagonist-bound CB 1 reveal marked structural rearrangements (C α r.m.s.d. of the overall structure without fusion protein: 3.52 Å; Fig. 4a ). Compared with the AM6538-bound CB 1 , the notable conformational change occurs in helices I and II. The extracellular part of helix I bends inwards by 6.6 Å and helix II rotates in by about 6.8 Å, respectively in the AM11542-bound structure (Fig. 4b) . Similarly, important conformational changes are also observed in the cytoplasmic part of the receptor, in which helix VI moves outwards by about 8 Å (Fig. 4b) , resembling the β 2 adrenergic receptor (β 2 AR)-G s complex 16 . This is the largest structural change, especially within the extracellular portion, observed in the solved agonist/antagonist-bound pairs of class A G-protein-coupled receptors (GPCRs) (Extended Data Table 3 ). Consequently, owing to the inward shifts of helices I/II, and the subsequent inward rotation of the side chains of Phe170 2.57 and Phe174 2.61 that occupy the gap pocket 2 ( Fig. 3b) , the volume of the ligand-binding pocket shrinks from 822 Å 3 in the antagonist-bound structure to 384 Å 3 in the agonist-bound complex, representing a 53% reduction (Fig. 2c, d , Extended Data Table 3 ).
The agonist-induced conformational changes, discussed above, probably trigger the activation and downstream signalling associated with CB 1 . From a more granular perspective, CB 1 seems to use an extended molecular toggle switch involving a synergistic conformational change between Phe200 3.36 and Trp356 6.48 , which we refer to as the 'twin toggle switch' (Fig. 4c) . In the AM6538-bound structure, Phe200 3.36 points away from the ligand-binding pocket and forms an aromatic stacking interaction with Trp356 6.48 , which may contribute to stabilization of the receptor in the inactive state (Fig. 4c) . While in the AM11542-bound structure, the cooperative rotation of helix III and the side-chain flipping of Phe200 3.36 lead the phenyl ring to point towards the ligand and form hydrophobic interactions with the C1′-gem-dimethyl group of AM11542 (Fig. 4c) . Simultaneously, the outwards rotation of helix VI leads the side chain of Trp356 6.48 to swing away from the ligands (Fig. 4c) , disrupting the π -π stacking of the side chains of Phe200 3.36 and Trp356 6.48 . Comparing previously proposed 'toggle switch' of Trp356 6.48 , the synergistic movement of two residues, Phe200 3.36 and Trp356 6.48 , during the activation of receptors has never been observed Letter reSeArCH before and we speculate that this twin toggle switch is related to CB 1 activation, a structural observation that is in agreement with a previous modelling study 17, 18 . To investigate whether the twin toggle switch concept exists in other receptors, we performed a sequence analysis among class A GPCRs that shows that CB 2 as well as certain chemokine receptors (such as CCR2 and CCR5), possess an aromatic residue at the appropriate position (Phe/Tyr 3.36 ) to synergize with the highly conserved tryptophan on helix VI (Trp 6.48 ). In addition, the highly conserved E/DRY motif and NPXXY motif are also rearranged in the AM11542 agonist-bound CB 1 structure. The polar network around the DRY motif is disrupted during activation (Fig. 4d) angle among all known agonist-bound (without G protein or G-protein mimics) class A GPCRs (Extended Data Fig. 6b) . Similarly, the most important rearrangement around NPXXY region is a partial 'unwinding' of helix VII around Tyr397 7.53 (Fig. 4d) . A notable feature of the CB 1 agonist bound structure is the large (53%) reduction in volume in the ligand-binding pocket between agonist-and antagonist-bound structures, and subsequent volume increase in the intracellular G-protein-binding site. Such plasticity in the orthosteric binding pocket enables CB 1 to respond to a diverse array of ligands with considerably different sizes, shapes and associated functions, consistent with the repertoire of CB 1 to modulate such varied physiological and psychological activities.
To investigate whether a similar feature exists in other receptors, the ligand-binding volume of all agonist-and antagonist-bound structural pairs in class A GPCRs are compared (Extended Data Table 3 ). Related to the ligand-binding volume change, we analysed the helices movement between antagonist-and agonist-bound structures in extracellular and intracellular halves. In most structural pairs, the extracellular half undergoes small changes while larger conformational changes in the intracellular half occur due to movements of helices VI, V and VII (Extended Data Fig. 6a ). As an exception to this minimal trigger, CB 1 has the largest ligand-binding pocket volume change, contributed mainly by the movements of the extracellular half of helices I and II. Large inwards bending (over 4 Å) of helix VI is also observed in the purinergic receptor P2Y 12 structure 19, 20 (Extended data Fig. 6a ). The balloon-like flexibility of CB 1 in the extracellular region may also occur in other GPCRs. Therefore, while designing GPCR agonists and antagonists using structure-based strategies, multiple, structurally varied receptor models should be considered.
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No statistical methods were used to predetermine sample size. However, for mutants in the cAMP accumulation assays, after an n = 3 was obtained, an additional power analysis was performed (alpha = 0.05; power = 80%) to determine the n required to have confidence in the values produced; additional curves were added as indicated. Synthesis of AM11542 and AM841: experimental procedures and spectroscopic data. Experimental procedures for steps a-m (Extended Data Fig. 1 ) are similar to those we reported earlier for closely related systems 9, 21, 22 . (6aR,9R,10aR)-3-(8-bromo-2-methyloctan-2-yl)-1-((tert-butyldimethylsilyl)oxy)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromene-9-carbaldehyde (12) . Colourless oil. 
{(6aR,9R,10aR)-3-(8-Bromo-2-methyloctan-2-yl)-1-[(tert-butyldimethylsilyl)oxy]-6,6-dimethyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-9-yl}methanol (13).
Colourless viscous oil. (14) . To a solution of 13 (210 mg, 0.36 mmol) in anhydrous THF (9 ml) at − 40 °C, under an argon atmosphere, was added tetra-n-butylammonium fluoride (0.72 ml, 0.72 mmol, 1 M solution in anhydrous THF). The reaction mixture was stirred for 30 min at the same temperature, and then quenched using a saturated aqueous NH 4 Cl solution. Extractive isolation with diethyl ether, and purification by flash column chromatography on silica gel (20-50% ethyl acetate in hexane) gave 14 (164 mg, 96% yield) as a white solid. Melting point = 68-70 °C. (15) . To a stirred solution of 14 (160 mg, 0.34 mmol) in anhydrous CH 3 Cl/CH 3 NO 2 (1:1 mixture, 6 ml) at room temperature, under an argon atmosphere was added N,N,N′,N′-tetramethylguanidinium azide (1.6 g, 10.2 mmol) and stirring was continued for 1 day. On completion, the reaction was quenched with water and diluted with . Experimental procedures for the synthesis and purification, along with spectroscopic and analytical data were reported earlier from our laboratory 8 . Purification of CB 1 -flavodoxin protein and crystallization in lipidic cubic phase. CB 1 -flavodoxin construction, expression and membrane preparation were performed using the same procedure as descried before 2 . In brief, the construct has truncations of residues 1-98, 307-331 and 415-472, the flavodoxin (PDB accession 1I1O, molecular mass 14.9 kDa, with Y98W mutation) fusion protein was fused to the truncated third intracellular loop of the human CNR1 (also known as CB1) gene. The resulting CB 1 -flavodoxin chimaera sequence was subcloned into a modified mammalian expression vector pTT5 that contains a haemagglutinin (HA) signal sequence, a Flag tag and 10× His tag, followed by a tobacco etch virus (TEV) protease cleavage site, before the N terminus of the chimaera sequence. The CNR1 gene was further modified by introducing four rationally designed mutations 23 , Thr210 3.46 Ala, Glu273 5.37 Lys, Thr283 5.47 Val and Arg340 6.32 Glu, using standard QuickChange PCR. The protein was expressed using the FreeStyle 293 Expression system (Invitrogen) in HEK293F cells for 48 h, and the membrane was washed repeatedly using hypotonic buffer with low and high salt. Notably, the receptor used for crystallization was capable of binding to [ This CB 1 construct yielded no signalling in signalling assays (not shown), which is probably due to the flavodoxin insert that prevents coupling secondary effectors. However, the individual point mutations did not interfere with agonist activity except for Thr210 3.46 Ala, which has been previously reported 23 . These controls are summarized in Extended Data Fig. 4c and Extended Data Table 2 .
6aR,9R,10aR)-3-(8-Bromo-2-methyloctan-2-yl)-9-(hydroxymethyl)-6,6-dimethyl6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-1-ol
6aR,9R,10aR)-3-(8-Azido-2-methyloctan-2-yl)-9-(hydroxymethyl)-6,6-dimethyl6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-1-ol
Purified membranes were thawed at room temperature and then incubated with 20 μ M corresponding ligand (AM11542 or AM841) in the presence of 1.0 mg ml −1 iodoacetamide, and EDTA-free protease inhibitor cocktail (Roche) for 30 min at room temperature, and then further incubated at 4 °C for 3 h. The membranes were then solubilized with 50 mM HEPES (pH 7.5), 500 mM NaCl, 1% (w/v) Letter reSeArCH lauryl maltose neopentyl glycol (LMNG, Anatrace) and 0.2% (w/v) cholesterol hemisucinate (CHS, Sigma-Aldrich) at 4 °C for 2.5-3.0 h. The supernatants containing the solubilized CB 1 proteins were isolated by high-speed centrifugation, and then incubated with TALON IMAC resin (Clontech) and 20 mM imidazole, at 4 °C overnight. The resin was washed with 15 column volumes of washing buffer I containing 25 mM HEPES (pH 7.5), 500 mM NaCl, 10% (v/v) glycerol, 0.1% (w/v) LMNG, 0.02% (w/v) CHS, 30 mM imidazole and 20 μ M AM11542 or AM841, and 5 column volumes of washing buffer II containing 25 mM HEPES (pH 7.5), 500 mM NaCl, 10% (v/v) glycerol, 0.03% (w/v) LMNG, 0.015% (w/v) CHS, 50 mM imidazole and 20 μ M AM11542 or AM841. The proteins were eluted by 2.5 column volumes of eluting buffer containing 25 mM HEPES (pH 7.5), 500 mM NaCl, 10% (v/v) glycerol, 0.01% (w/v) LMNG, 0.002% (w/v) CHS, 250 mM imidazole and 20 μ M AM11542 or AM841. PD MiniTrap G-25 column (GE Healthcare) was used to remove imidazole. The protein was then treated overnight with TEV protease to cleave the N-terminal Flag/His tags from the proteins. Finally, the purified CB 1 protein together with TEV protease was concentrated to about 35 mg ml −1 with a 100 kDa cutoff concentrator (Sartorius) and used in crystallization trials. The protein yield and monodispersity were tested by analytical size exclusion chromatography.
Protein samples were reconstituted into lipidic cubic phase (LCP) by mixing with molten lipid (90% (w/v) monoolein and 10% (w/v) cholesterol) at a protein/ lipid ratio of 2:3 (v/v) using a mechanical syringe mixer 24 . LCP crystallization trials were performed using an NT8-LCP crystallization robot (Formulatrix). 96-well glass sandwich plates were incubated and imaged at 20 °C using an automatic incubator/imager (RockImager 1000, Formulatrix). For the CB 1 -AM11542 complex, the crystals grew in conditions of 0.1 M sodium cacodylate trihydrate pH 6.4, 300-350 mM C 4 H 4 KNaO 6 , 30% PEG400 and grew to the full size within 1 week. For the CB 1 -AM841 complex, the crystals appeared after 2 days in 0.1 M sodium cacodylate trihydrate pH 6.2, 120 mM C 6 H 5 Na 3 O 7 ·2H 2 O, 30% PEG400 and 100 mM glycine and reached their full size after 1 week. The crystals were harvested using micromounts (MiTeGen) and flash-frozen in liquid nitrogen. Data collection, structure solution and refinement. X-ray diffraction data were collected at GM/CA-CAT beamline 23ID-B at the Advanced Photon Source (APS), Argonne National Laboratory IL, using an Eiger 16 M detector (X-ray wavelength 1.0000 Å) and at beamline X06SA of the Swiss Light Source. The crystals were exposed with a 10 μ m minibeam for 0.2 s and 0.2° oscillation per frame, a rastering system was applied to find the best diffracting parts of single crystals 25, 26 . XDS 27 was used for integrating and scaling data from the 16 crystals for the CB 1 -AM11542 complex and 10 crystals for the CB 1 -AM841 complex. Initial phase information was obtained by molecular replacement with Phaser 28 using the receptor portion of CB 1 (PDB code 5TGZ) and flavodoxin structure (PDB code 1I1O) as search models. Refinement was performed with Phenix 29 and Buster 30 followed by manual examination and rebuilding of the refined coordinates in the program COOT 31 using both | 2F o | − | F c | and | F o | − | F c | maps. Radioligand binding assay. Radioligand binding to determine agonist affinity and wash resistant residency was determined as previously described 2 using [ 3 H]CP55,940 (specific activity: 81.1 Ci mmol −1 , NDSP, NIDA) and an excess of CP55,940 to determine nonspecific binding. Specifically for wash out experiments at the wild-type CB 1 , membranes were incubated at 37 °C for 1 h in the presence of vehicle (buffer with 1% DMSO), 1 nM AM11542, 10 nM AM841 or 4 nM CP55,940 followed by resuspension in assay buffer containing 1% BSA and incubated at 37 °C for 30 min (to remove non-specifically bound ligand); this was repeated twice to wash away bound ligands before the saturation radioligand binding assay on membranes (37 °C for 1-4 h as indicated). K i and B max calculations were performed by nonlinear regression analysis using GraphPad Prism 7.0, n = 3-6. Wild-type and mutant CB 1 -CHO cell line generation for functional studies. Cell line generation and maintenance was conducted as described previously 2 and briefly described here. The N terminus 3× HA -tagged CB 1 cDNA was obtained from http://cDNA.org and subcloned into a mouse stem-cell virus for cell line transduction (pMSCV-puro, Clontech). Point mutations were introduced to the N terminus 3× HA-tagged CB 1 cDNA in MSCV retroviral vector by using Q5 Site-Directed Mutagenesis kit (New England Biolabs) (F177A, L193A, D213A, Y275A, Y275F, F379A, F379W, S383A). Generation of F379 mutants was described previously 2 . Wild-type and mutant CB 1 constructs were packaged into retrovirus via Phoenix package system (Allele Biotechnology cat. no. ABP-RVC-10001), and the produced retroviruses were applied to CHO-K1 (ATCC cat. no. CCL-61) cells for gene transduction. Cells were maintained in DMEM/F-12 media supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 5 mg ml −1 puromycin (Invitrogen) for stable line selection at 37 °C (5% CO 2 and 95% relative humidity). Cell lines were negative for mycoplasma. See Extended Data Fig. 4a for primers used to make mutant CB 1 receptors.
Quantitative flow cytometry. Validation of cell-surface expression of the HA-tagged wild-type and mutant CB 1 receptors expressed in CHO-K1 cells was obtained by anti-HA antibody staining followed by quantitative flow cytometry and visually confirmed by confocal imaging. In brief, cells were serum-starved 30 min at 37 °C and collected in 5 mM EDTA and fixed with 4% paraformaldehyde for 10 min at 4 °C. Cells were washed twice with PBS and resuspended in PBS containing 1% FBS and 5 mM EDTA. Cells were incubated with anti-HA AlexaFluor488-conjugated antibody (1:1,000) for 30 min at 4 °C, washed twice with PBS and again resuspended in PBS containing 1% FBS and 5 mM EDTA. Fluorescence was recorded using a BD Canto flow cytometer (excitation/emission: 488/525 nm). Approximately 50,000 events were recorded for each cell line. Data are expressed as the percentage of positive-fluorescent cells from 50,000 events recorded (3× HA-CB 1 CHO wild-type = 65%) and relative to 3× HA-CB 1 wild-type CHO (100%). Untransfected CHO cells had 0% fluorescence. See Extended Data Fig. 4a for primers used to make mutant CB 1 receptors and surface expression comparisons of all mutants reported herein. See Supplementary Fig. 1 for flow cytometry graphs. cAMP accumulation assay. Inhibition of forskolin-stimulated cAMP was determined using the CISBIO cAMP Homogeneous Time-Resolved Fluorescence resonance energy transfer (FRET) (HTRF) (Cisbio Assays) as previously described Molecular dynamics simulation was performed using GROMACS 5.1.2 35 , using force field Amber 14 (AMBER 2017; http://ambermd.org/). CB 1 in complex with each agonist in the pocket (binding modes predicted by molecular docking) was embedded into a pre-equilibrated POPC (1-palmytoil-2-oleoyl-sn-glycerol-3-phosphatidylcholine) lipid bilayerusing the membed tool in GROMACS program. The topology files of ligands and POPC molecules were generated using AmberTools in UCSF Chimera program 36 version 1.10.2 and converted to GROMACS format with ACPYPE tool 37 . The systems were solvated with water, sodium ions were added to 0.15 M in water, and chloride ions were added to neutralize the system. Molecular dynamics simulations were performed in the NPT ensemble, at a temperature of 310 K and pressure of 1 atm using semi-isotropic coupling. First, each system was balanced position-restrained MD for 15 ns (total energy was stable). Then 1 μ s molecular dynamics simulations with no position restraints were performed to each system for two independent runs, and these trajectories are used for analysis. Ligand r.m.s.d. value was calculated with protein C α atoms superimposed to the starting structure.
Comparison of agonist-and antagonist-bound class A GPCRs structures.
Seventeen crystal structures of seven GPCRs that have both agonist-and antagonist-bound structures were selected from the PDB 38 . Among them, there are 24, 32 and 21 structures for the β 2 -adrenergic receptor, rhodopsin and A 2A adenosine receptor, respectively. To pick representative structures of the three GPCRs, their PDB structures were clustered by R package Bio3D 39 based on r.m.s.d. differences. The following structures from each cluster were manually picked. Agonist/ arrestin-bound structures include CB 1 (this study; PDB code 5XRA), β 2 -adrenergic receptor (PDB codes 3SN6, 4LDL), μ -opioid receptor (PDB code 5C1M), M 2 muscarinic receptor (PDB code 4MQS), rhodopsin (PDB codes 2X72, 4ZWJ (arrestin-bound)), A 2A adenosine receptor (PDB codes 3QAK, 5G53) and P 2Y purinoceptor 12 (PDB code 4PXZ). Antagonist-bound structures include CB 1 (PDB code 5TGZ), β 2 -adrenergic receptor (PDB code 3NY8), μ -opioid receptor (PDB code 4DKL), M 2 muscarinic receptor (PDB code 3UON), rhodopsin (PDB code 1U19), A 2A adenosine receptor (PDB code 4EIY) and P 2Y purinoceptor 12 (PDB code 4NTJ). Binding pocket volume comparison and r.m.s.d. analysis of solved representative agonist-and antagonist-bound  pairs of seven class A GPCrs 
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